FDA Approves Keytruda Combo for Muscle Invasive Bladder Cancer
MRK sits 62% above its 52-week low of $76.66 on light trading volume (0.1× avg).
Summary
The FDA approved pembrolizumab (Keytruda) in combination with enfortumab vedotin for muscle invasive bladder cancer, expanding Keytruda's label into a new, earlier-stage setting. This follows a string of positive regulatory and clinical wins for Merck's oncology portfolio, including recent Keytruda-based approvals in renal cell carcinoma and promising five-year data in other tumor types. Bladder cancer represents a significant market opportunity, and this approval strengthens Keytruda's position ahead of upcoming patent cliffs. The decision came via a priority review, underscoring the regimen's clinical value.
At the time of this announcement, MRK was trading at $124.47 on NYSE in the Life Sciences sector, with a market capitalization of approximately $307.4B. The 52-week trading range was $76.66 to $130.29. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.